Biopharma firm Xeris has received U.S. Food and Drug Administration (FDA) approval for its liquid glucagon Gvoke VialDx to be used as a diagnostic aid during abdominal radiologic examinations.
GVoke Vial Dx is primarily indicated as an antihypoglycemic agent for subcutaneous use for the treatment of severe hypoglycemia in adult and pediatric patients two years and older with diabetes.
In addition, Xeris said that it has made an agreement with American Regent in which Xeris will be responsible for the production of Gvoke VialDx, while American Regent will be responsible for its commercialization in the U.S.
Gvoke VialDx is expected to become available in the third quarter of 2025, the company added.